Tema Obesity & Cardiometabolic ETF Rating $28.62 -0.19 (-0.66%) As of 03:55 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsRatingsBuy This Stock Tema Obesity & Cardiometabolic ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.76Holdings in HRTS have an aggregate rating of Moderate Buy based on 652 analyst ratings issued in the past year covering 39 companies (79.7% of the portfolio).HRTS Aggregate Price Target$28.62High Prediction$28.62Average Prediction$28.62Low Prediction$28.62Holdings in HRTS have an aggregate price target of $28.62 and a range of $28.62 to $28.62 covering 39 companies (79.7% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy23 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Obesity & Cardiometabolic ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 39 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.71%LLYEli Lilly and Company$807.62-1.4%4.9542 of 5 stars2.76$1,011.37 25.2%21Trending News4.41%ABTAbbott Laboratories$133.99-1.2%4.9556 of 5 stars2.80$142.61 6.4%20Positive NewsDividend AnnouncementAnalyst Forecast4.06%RHHBYRoche$41.32-1.5%N/A2.577News Coverage3.61%UNHUnitedHealth Group$307.84-1.1%4.9971 of 5 stars2.60$426.52 38.6%25Positive News3.39%BBIOBridgeBio Pharma$41.14+3.4%4.6839 of 5 stars2.92$57.36 39.4%12Gap Up3.17%BSXBoston Scientific$101.49+1.8%4.5871 of 5 stars3.09$116.09 14.4%23Positive NewsAnalyst Forecast3.11%VRTXVertex Pharmaceuticals$450.91-1.0%4.59 of 5 stars2.57$515.04 14.2%30Positive News3.03%GILDGilead Sciences$110.83+0.8%4.9069 of 5 stars2.78$110.55 -0.3%27Trending NewsEx-Dividend2.89%MDTMedtronic$87.92+0.7%4.83 of 5 stars2.59$97.87 11.3%17Positive NewsAnalyst ForecastShort Interest ↓2.70%CRNXCrinetics Pharmaceuticals$31.20-1.8%3.5319 of 5 stars2.91$74.56 139.0%11Positive News2.49%AMGNAmgen$295.56+0.1%4.4653 of 5 stars2.38$309.22 4.6%24Positive News2.49%TMOThermo Fisher Scientific$405.15+0.6%4.9709 of 5 stars2.80$605.30 49.4%20Positive NewsEx-Dividend2.40%MRKMerck & Co., Inc.$80.97+0.1%4.9964 of 5 stars2.43$109.19 34.9%21Positive News2.18%ABBVAbbVie$190.91-0.1%4.9004 of 5 stars2.81$211.29 10.7%27Trending News2.11%BMYBristol-Myers Squibb$48.65-2.2%4.8168 of 5 stars2.32$58.00 19.2%22Positive NewsAnalyst Revision2.04%PODDInsulet$306.59+0.6%4.2974 of 5 stars2.83$321.00 4.7%18Analyst Downgrade2.04%EWEdwards Lifesciences$74.80-0.5%4.5761 of 5 stars2.40$80.20 7.2%25Positive News1.98%DHRDanaher$201.14+0.2%4.8248 of 5 stars2.80$248.17 23.4%20Positive News1.89%MCKMcKesson$719.53-1.2%4.3783 of 5 stars2.87$694.38 -3.5%15Positive NewsAnalyst Downgrade1.89%REGNRegeneron Pharmaceuticals$522.68-1.2%4.8488 of 5 stars2.85$836.48 60.0%26Analyst Revision1.89%ALNYAlnylam Pharmaceuticals$308.78+0.3%4.248 of 5 stars2.77$319.58 3.5%26Positive NewsAnalyst Downgrade1.49%CYTKCytokinetics$33.78-1.7%4.2787 of 5 stars2.93$70.92 110.0%151.41%DXCMDexCom$83.00+1.2%4.8007 of 5 stars2.95$98.50 18.7%22Positive NewsAnalyst Forecast1.32%IONSIonis Pharmaceuticals$35.24-1.0%4.3902 of 5 stars2.68$57.59 63.4%191.30%ASNDAscendis Pharma A/S$177.71+4.0%3.3912 of 5 stars3.00$220.67 24.2%15Analyst Forecast1.22%MASIMasimo$162.54+0.8%3.972 of 5 stars2.83$191.60 17.9%61.07%ARWRArrowhead Pharmaceuticals$15.71-0.2%3.6198 of 5 stars2.75$43.71 178.3%8Positive NewsAnalyst Upgrade1.05%VKTXViking Therapeutics$26.96+3.4%4.4926 of 5 stars3.00$87.15 223.3%14Positive News1.02%AKROAkero Therapeutics$55.75+0.2%3.6266 of 5 stars3.00$82.50 48.0%71.00%MDGLMadrigal Pharmaceuticals$285.06-3.6%4.1728 of 5 stars2.89$420.63 47.6%9Positive News0.95%GPCRStructure Therapeutics$20.57-5.1%2.283 of 5 stars3.00$76.50 271.9%70.91%MIRMMirum Pharmaceuticals$50.42+1.6%3.2381 of 5 stars3.17$60.73 20.4%12Positive News0.86%INSMInsmed$101.59+2.9%3.3232 of 5 stars3.00$104.81 3.2%18Insider TradeAnalyst RevisionHigh Trading Volume0.83%WSTWest Pharmaceutical Services$224.36+1.1%4.7696 of 5 stars3.00$332.50 48.2%8Trending News0.64%SRRKScholar Rock$32.13-1.0%4.2931 of 5 stars3.14$42.67 32.8%70.35%MTSRMetsera$26.87-8.5%N/A3.00$50.00 86.1%4Gap Up0.32%MREOMereo BioPharma Group$2.761.8677 of 5 stars3.17$7.67 177.8%60.26%NTLAIntellia Therapeutics$8.96+7.8%4.6088 of 5 stars2.67$34.95 290.1%21Analyst ForecastGap Up0.18%RCKTRocket Pharmaceuticals$2.88-1.7%4.9476 of 5 stars2.41$19.57 579.6%17Trending News This page (NYSEARCA:HRTS) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Obesity & Cardiometabolic ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Obesity & Cardiometabolic ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTS Stock Free HRTS Stock Alerts